6-pyridin-2-yl-hexan-1-ol | 79032-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-pyridin-2-yl-hexan-1-ol
• 英文别名: 6-(2-pyridyl)-hexan-1-ol；6-pyridin-2-ylhexan-1-ol
• CAS: 79032-28-3
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: YZQDHWVZGADPQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-pyridin-2-yl-hexan-1-ol 在 potassium dihydrogenphosphate 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三苯基膦 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.59h， 生成 Methyl 3-cyano-3-hydroxy-4-(6-pyridin-2-ylhexylsulfanyl)butanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 platinum(IV) oxide 氢气 、 二异丁基氢化铝 、 dimsyl sodium 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 2.0h， 生成 6-pyridin-2-yl-hexan-1-ol
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• A general synthesis of alkylpyridines
  作者：Beatriz Iglesias、Rosana Alvarez、Angel R de Lera

  DOI：10.1016/s0040-4020(01)00170-3

  日期：2001.4

  The hydroboration of alkenes, followed by the coupling of the B-alkyl-9-borabicyclo[3.3.1]nonane derivatives with bromopyridines constitutes an efficient procedure for the attachment of functionalized alkyl chains to the pyridine nucleus.

  烯烃的硼氢化，然后将B-烷基-9-硼环[3.3.1]壬烷衍生物与溴吡啶偶联，是将官能化烷基链连接到吡啶核上的有效方法。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Phenethanolamine derivatives
  申请人：Glaxo Group Ltd.

  公开号：US04963564A1

  公开（公告）日：1990-10-16

  The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## (wherein Q.sup.1 represents a straight or branched C.sub.1-3 alkylene group), ##STR3## (where Q.sup.2 represents a group R.sup.5 CO--, R.sup.5 NHCO--, R.sup.5 R.sup.6 NSO.sub.2 -- or R.sup.7 SO.sub.2 --, where R.sup.5 and R.sup.6 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.7 represents a C.sub.1-3 alkyl group), or ##STR4## X represents a bond, or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene chain, and Y represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10; R represents a hydrogen atom or C.sub.1-3 alkyl group; R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group; with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is (are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, halogen, --NR.sup.3 R.sup.4 and --COR.sup.8 ; where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--; and R.sup.8 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4. The compounds have a stimulant action at .beta.2-adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  本发明提供了一般式（I）的化合物以及其生理上可接受的盐和溶剂化物，其中Z表示以下基团之一：##STR2##（其中Q.sup.1表示直链或支链的C.sub.1-3烷基），##STR3##（其中Q.sup.2表示R.sup.5 CO--、R.sup.5 NHCO--、R.sup.5 R.sup.6 NSO.sub.2 --或R.sup.7 SO.sub.2 --基团，其中R.sup.5和R.sup.6分别表示氢原子或C.sub.1-3烷基，而R.sup.7表示C.sub.1-3烷基），或##STR4## X表示键或C.sub.1-7烷基、C.sub.2-7烯基或C.sub.2-7炔基链，而Y表示键或C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基链，但链X和链Y中碳原子的总和不超过10；R表示氢原子或C.sub.1-3烷基；R.sup.1和R.sup.2分别表示氢原子或C.sub.1-3烷基，但R.sup.1和R.sup.2中碳原子的总和不超过4；而Het表示苯并杂芳基或单环杂芳基，其中杂芳基是5或6元环并含有1、2或3个杂原子，其中一个是氮原子，而其他的是氮、氧或硫原子，而且基团Het可以选择地被1或2个从C.sub.1-4烷基、C.sub.1-4烷氧基、羟基、卤素、--NR.sup.3 R.sup.4和--COR.sup.8中选择的基团所取代；其中R.sup.3和R.sup.4分别表示氢原子或C.sub.1-4烷基，或--NR.sup.3 R.sup.4形成饱和杂环氨基基团，该基团具有5-7环成员，而且可以在环中选择地含有一个或多个从--O--或--S--或--NH--或--N(CH.sub.3)--中选择的原子，而R.sup.8表示羟基、C.sub.1-4烷氧基或--NR.sup.3 R.sup.4。这些化合物对β2-肾上腺素能受体具有刺激作用，可用于治疗与可逆性气道阻塞相关的疾病，如哮喘和慢性支气管炎。
• Enhancing Substrate–Metal Catalyst Affinity via Hydrogen Bonding: Pd(II)-Catalyzed β-C(sp³)–H Bromination of Free Carboxylic Acids
  作者：Liang Hu、Guangrong Meng、Xiangyang Chen、Joseph S. Yoon、Jing-Ran Shan、Nikita Chekshin、Daniel A. Strassfeld、Tao Sheng、Zhe Zhuang、Rodolphe Jazzar、Guy Bertrand、K. N. Houk、Jin-Quan Yu

  DOI：10.1021/jacs.3c04223

  日期：2023.8.2

  While hydrogen bonding has been harnessed to bias site selectivity in existing C(sp2)–H activation reactions, the potential for designing catalysts with hydrogen bond donors (HBDs) to enhance catalyst–substrate affinity and, thereby, facilitate otherwise unreactive C(sp3)–H activation remains to be demonstrated. Herein, we report the discovery of a ligand scaffold containing a remote amide motif that

  实现足够的底物-金属催化剂亲和力是开发弱配位天然底物的合成有用的C-H活化反应的基本挑战。虽然氢键在现有的 C(sp 2 )–H 活化反应中已被利用来偏置位点选择性，但设计具有氢键供体 (HBD) 的催化剂以增强催化剂与底物的亲和力，从而促进原本不活泼的 C(sp 2 )–H 活化反应的潜力3 )–H 激活仍有待证明。在此，我们报告了含有远程酰胺基序的配体支架的发现，该配体支架可以与脂肪酸底物形成有利的间大环氢键相互作用。这种配体支架的实用性通过α-叔和α-季游离羧酸的前所未有的C(sp 3 )–H溴化的发展得到证明，该溴化以极高的单选择性进行。NHAc氢键供体和配位喹啉配体之间的几何关系对于形成类间大环芳氢键相互作用至关重要，这为未来采用二次相互作用的催化剂设计提供了指导。
• 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1555267A1

  公开（公告）日：2005-07-20

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and a typical acid-fast bacteria.

  本发明提供了由以下通式代表的 2，3-二氢-6-硝基咪唑并[2，1-b]恶唑化合物： 其中R1代表氢原子或C1-C6烷基，n代表0至6的整数，R2代表基团-OR3或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合，从而形成通式(H)代表的螺环： 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和典型的耐酸细菌有很好的杀菌作用。